USAMRICD (United States Army Medical Research Institute of Chemical Defense)
The United States Army Medical Research Institute of Chemical Defense (USAMRICD) located in Aberdeen Proving Ground, Maryland, is a research and training laboratory dedicated to advancing the treatments that alleviate the suffering caused by chemical weapons and developing new materials that aid in those treatments. Researchers at the laboratory include experts in physiology, toxicology, pathology and biochemistry.
Established in 1922 as part of the Army Medical Department, the laboratory was responsible for treating chemical weapon casualties during World War I. In the 1960s the division was renamed the U.S. Army Biomedical Laboratory. The laboratory was put under the command of the U.S. Army Surgeon General in 1979 and received its
current name in 1981. Today, the USAMRICD is one of six laboratories and institutes under the authority of the U.S. Army Medical Research and Materiel Command.
Researchers at the USAMRICD have made hundreds of contributions to the scientific literature and have produced technical bulletins on procedures for collecting, handling, shipping, and preparing samples of chemical agents. The laboratory also operates a chemical surety facility. Along with its research charge, the USAMRICD is also a training institution. The Chemical Casualty Care Division (CCCD) provides courses in the management and treatment of chemical weapons injuries to medical professionals. Courses are offered at the laboratory, at off-site locations and as computer-based training. Much of the educational and training work of the USAMRICD is done in partnership with the United States Army Medical Research Institute of Infectious Disease (USAMRIID) in Fort Detrick, Maryland, which is the Army's primary laboratory for research into biological warfare agents.
█ FURTHER READING:
United States Army < http://mrmc-www.army.mil/ > (April 10, 2003).
United States Army Medical Research Institute of Chemical Defense < http://chemdef.apgea.army.mil/ > (April 10, 2003).